These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 25360562)

  • 1. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
    Claes N; Dhaeze T; Fraussen J; Broux B; Van Wijmeersch B; Stinissen P; Hupperts R; Hellings N; Somers V
    PLoS One; 2014; 9(10):e111115. PubMed ID: 25360562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod modulates peripheral effector and regulatory T cells in MS patients.
    Serpero LD; Filaci G; Parodi A; Battaglia F; Kalli F; Brogi D; Mancardi GL; Uccelli A; Fenoglio D
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1106-13. PubMed ID: 23649711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.
    Sato DK; Nakashima I; Bar-Or A; Misu T; Suzuki C; Nishiyama S; Kuroda H; Fujihara K; Aoki M
    J Neuroimmunol; 2014 Mar; 268(1-2):95-8. PubMed ID: 24507619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of fingolimod on B-cell populations in multiple sclerosis.
    Nakamura M; Matsuoka T; Chihara N; Miyake S; Sato W; Araki M; Okamoto T; Lin Y; Ogawa M; Murata M; Aranami T; Yamamura T
    Mult Scler; 2014 Sep; 20(10):1371-80. PubMed ID: 24526661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
    Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    Hjorth M; Dandu N; Mellergård J
    PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.
    Ferraro D; De Biasi S; Vitetta F; Simone AM; Federzoni L; Borghi V; Cossarizza A; Nichelli PF; Sola P
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1059-61. PubMed ID: 24163092
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
    Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
    Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.
    Miyazaki Y; Niino M; Fukazawa T; Takahashi E; Nonaka T; Amino I; Tashiro J; Minami N; Fujiki N; Doi S; Kikuchi S
    Clin Immunol; 2014 Apr; 151(2):127-35. PubMed ID: 24607506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
    Kira J; Itoyama Y; Kikuchi S; Hao Q; Kurosawa T; Nagato K; Tsumiyama I; von Rosenstiel P; Zhang-Auberson L; Saida T
    BMC Neurol; 2014 Jan; 14():21. PubMed ID: 24475777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
    Fazekas F; Berger T; Fabjan TH; Ledinek AH; Jakab G; Komoly S; Kraus J; Kurča E; Kyriakides T; Lisý L; Milanov I; Panayiotou P; Jazbec SS; Taláb R; Traykov L; Turčáni P; Vass K; Vella N; Havrdová E
    Wien Med Wochenschr; 2012 Aug; 162(15-16):354-66. PubMed ID: 22895849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy.
    Yokoseki A; Saji E; Arakawa M; Hokari M; Ishiguro T; Yanagimura F; Ishihara T; Okamoto K; Nishizawa M; Kawachi I
    Mult Scler; 2013 Aug; 19(9):1230-3. PubMed ID: 23519973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
    Al-Hashel J; Ahmed SF; Behbehani R; Alroughani R
    CNS Drugs; 2014 Sep; 28(9):817-24. PubMed ID: 25011422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Clin Neurol Neurosurg; 2014 Apr; 119():17-20. PubMed ID: 24635919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
    Saida T; Kikuchi S; Itoyama Y; Hao Q; Kurosawa T; Nagato K; Tang D; Zhang-Auberson L; Kira J
    Mult Scler; 2012 Sep; 18(9):1269-77. PubMed ID: 22354739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.